Literature DB >> 30074291

European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management.

Winfried Häuser1,2, David P Finn3, Eija Kalso4, Nevenka Krcevski-Skvarc5, Hans-Georg Kress6, Bart Morlion7, Serge Perrot8, Michael Schäfer9, Chris Wells10, Silviu Brill11.   

Abstract

Cannabis-based medicines are being approved for pain management in an increasing number of European countries. There are uncertainties and controversies on the role and appropriate use of cannabis-based medicines for the management of chronic pain. EFIC convened a European group of experts, drawn from a diverse range of basic science and relevant clinical disciplines, to prepare a position paper to empower and inform specialist and nonspecialist prescribers on appropriate use of cannabis-based medicines for chronic pain. The expert panel reviewed the available literature and harnessed the clinical experience to produce these series of recommendations. Therapy with cannabis-based medicines should only be considered by experienced clinicians as part of a multidisciplinary treatment and preferably as adjunctive medication if guideline-recommended first- and second-line therapies have not provided sufficient efficacy or tolerability. The quantity and quality of evidence are such that cannabis-based medicines may be reasonably considered for chronic neuropathic pain. For all other chronic pain conditions (cancer, non-neuropathic noncancer pain), the use of cannabis-based medicines should be regarded as an individual therapeutic trial. Realistic goals of therapy have to be defined. All patients must be kept under close clinical surveillance. As with any other medical therapy, if the treatment fails to reach the predefined goals and/or the patient is additionally burdened by an unacceptable level of adverse effects and/or there are signs of abuse and misuse of the drug by the patient, therapy with cannabis-based medicines should be terminated. SIGNIFICANCE: This position paper provides expert recommendations for nonspecialist and specialist healthcare professionals in Europe, on the importance and the appropriate use of cannabis-based medicines as part of a multidisciplinary approach to pain management, in properly selected and supervised patients.
© 2018 European Pain Federation - EFIC®.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30074291     DOI: 10.1002/ejp.1297

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  34 in total

1.  [High-dose dronabinol treatment vs. medicinal cannabis flowers].

Authors:  Christoph Wendelmuth; Knud Gastmeier
Journal:  Schmerz       Date:  2019-10       Impact factor: 1.107

2.  [The green rush-worse than feared? : Data on the misuse of medical cannabis].

Authors:  Christoph Maier; Gerd Glaeske
Journal:  Schmerz       Date:  2021-05-27       Impact factor: 1.107

3.  [A weakly negative recommendation is not an absolute "no" : Comment on AWMF guideline recommendations for cannabis-based medicines in fibromyalgia syndrome].

Authors:  W Häuser; F Petzke; M Nothacker
Journal:  Schmerz       Date:  2018-10       Impact factor: 1.107

Review 4.  [Cannabis-based medicines for chronic pain: indications, selection of drugs, effectiveness and safety : Experiences of pain physicians in Saarland].

Authors:  Patric Bialas; Beate Drescher; Sven Gottschling; Stephanie Juckenhöfel; Dieter Konietzke; Wolfgang Kuntz; Isabell Kühne-Adler; Heidi Merl-Ripplinger; Diether Preisegger; Kathrein Schneider; Manfred Strauß; Patrick Welsch; Winfried Häuser
Journal:  Schmerz       Date:  2019-10       Impact factor: 1.107

5.  [Cannabis].

Authors:  Peter Cremer-Schaeffer; Winfried Häuser
Journal:  Schmerz       Date:  2019-10       Impact factor: 1.107

6.  Why Marijuana Won't Fix the Opioid Epidemic.

Authors:  Kenneth Finn
Journal:  Mo Med       Date:  2019 Sep-Oct

7.  [Medicinal cannabis and cannabis-based medication: an appeal to physicians, journalists, health insurances, and politicians for their responsible handling].

Authors:  Winfried Häuser; Eva Hoch; Frank Petzke; Rainer Thomasius; Lukas Radbruch; Anil Batra; Claudia Sommer; Ursula Havemann-Reinecke
Journal:  Schmerz       Date:  2019-10       Impact factor: 1.107

8.  Using cannabis for pain management after spinal cord injury: a qualitative study.

Authors:  John A Bourke; Victoria J Catherwood; Joanne L Nunnerley; Rachelle A Martin; William M M Levack; Bronwyn L Thompson; Richard H Acland
Journal:  Spinal Cord Ser Cases       Date:  2019-10-08

Review 9.  Medical Cannabis for Older Patients.

Authors:  Amir Minerbi; Winfried Häuser; Mary-Ann Fitzcharles
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

Review 10.  [Position paper on medical cannabis and cannabis-based medicines in pain medicine].

Authors:  Frank Petzke; Matthias Karst; Knud Gastmeier; Lukas Radbruch; Eva Steffen; Winfried Häuser
Journal:  Schmerz       Date:  2019-10       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.